⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

November 23, 2021Annals of the Rheumatic DiseasesOpen Access

Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

Nct03671148.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Östör et al. (2021) studied this question.

synapsesocial.com/papers/69d77ba1f44a16d01ef3154f https://doi.org/10.1136/annrheumdis-2021-221048

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

1Minimally Important Difference of Health Assessment Questionnaire in Psoriatic Arthritis: Relating Thresholds of Improvement in Functional Ability to Patient-rated Importance and SatisfactionRCT · 2011 · 126 citations
2Subcutaneous anti-TNF alfa induced sustained minimal disease activity and remission in psoriatic arthritis patients: a retrospective studyRetrospective Study · 2016 · 15 citations
3Efficacy and safety of risankizumab vs. secukinumab in patients with moderate‐to‐severe plaque psoriasis (IMMerge): results from a phase III, randomized, open‐label, efficacy–assessor‐blinded clinical trial*RCT · 2020 · 212 citations